PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Globe Newswire•12/08/2026•07:30 ET
0
Whiz Insights
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and Near-Term Milestones Achieved Following NDA Acceptance, with Over $290 Million in Additional Milestones Plus Tiered Royalties Up to Mid-Twenties Percentages
Get started
Create a free account to read the full story.